U.S. Pharma Stock News

Autohome FY 2025 earnings in focus Autohome (NYSE:ATHM) has wrapped up FY 2025 with fourth quarter revenue of about C¥1,462 million and basic EPS of roughly C¥1.94, set against a trailing twelve month EPS of C¥13.40 on revenue of about C¥6,452 million. The company has reported quarterly revenue in a range from C¥1,454 million to C¥1,778 million across FY 2025, with basic EPS between C¥1.94 and C¥3.58, giving investors a clear view of how top line and per share earnings have moved through the...

Catalyst Pharmaceuticals (NasdaqCM:CPRX) reported record full year and Q4 2025 results, highlighting organic growth across its portfolio. The company noted continued market uptake of its lead rare disease treatments, including AGAMREE and FIRDAPSE. Management discussed how recent alliances and product momentum position Catalyst within the rare disease treatment space. Catalyst Pharmaceuticals focuses on therapies for rare neurological and neuromuscular conditions, an area where treatment...

Alto Ingredients (ALTO) closed out FY 2025 with Q4 revenue of US$232 million and basic EPS of US$0.29, alongside net income of US$21.8 million, while on a trailing twelve month basis EPS sat at US$0.18 on revenue of US$917.9 million and net income of US$13.3 million. Over the past four quarters, the company has seen quarterly revenue range between US$218.4 million and US$241.0 million, with EPS swinging from losses of US$0.16 and US$0.15 in Q1 and Q2 2025 to positive readings of US$0.19 and...

Veeva Systems (VEEV) has wrapped up FY 2026 with Q4 revenue of US$836.0 million and basic EPS of US$1.49, backed by trailing twelve month revenue of US$3.2 billion and EPS of US$5.55. The company has seen revenue move from US$699.2 million in Q3 FY 2025 to US$835.9 million in Q4 FY 2026, while quarterly basic EPS stepped up from US$1.15 to US$1.49 over the same stretch, setting up a story that hinges on how consistently those earnings translate into cash and margin resilience. See our full...

Intro paragraph Enhabit (EHAB) just wrapped up FY 2025 with Q4 revenue of US$270.4 million and a basic EPS loss of US$0.76, as the company continued to report negative net income of US$38.7 million for the quarter. Over recent periods, revenue has moved from US$258.2 million in Q4 2024 to US$270.4 million in Q4 2025, while basic EPS shifted from a loss of US$0.92 to a loss of US$0.76. This sets up a results season where investors are watching how consistently the business can translate its...

Invivyd (IVVD) just closed out FY 2025 with fourth quarter revenue of US$17.2 million and a basic EPS loss of US$0.04, alongside net income excluding extra items of a US$11.1 million loss. Over the past few quarters, the company has seen revenue move from US$11.3 million in Q1 2025 to US$13.1 million in Q3 and US$17.2 million in Q4, while quarterly basic EPS moved from a loss of US$0.14 to US$0.06 and then US$0.04. This sets up a results season in which investors are likely to focus on how...

Tesla snapshot and recent returns Tesla (TSLA) is trading around US$405.55, with a 1 day move close to flat, a small gain over the past week, and slight declines over the past month and past 3 months. See our latest analysis for Tesla. That recent softness in the share price comes after a stronger run, with a 1 year total shareholder return of 54.4% and a 3 year total shareholder return of about 1.3x, suggesting momentum has cooled even though long term holders have still seen substantial...

What Amphenol's Recent Returns Tell You Amphenol (APH) has been moving in different directions across timeframes, with a 2.63% gain over the past day contrasted with weaker momentum over the week, month, and past 3 months. For longer term holders, the picture looks different, with the stock showing very large total return over 1 year and multiples of that over 3 and 5 years, which raises questions about how current pricing lines up with fundamentals. See our latest analysis for Amphenol. With...

Arcus Biosciences (NYSE:RCUS) reported new clinical and biomarker data for its CD73 inhibitor casdatifan in late line kidney cancer. The company highlighted strong efficacy signals in renal cell carcinoma and a tight link between biomarker suppression and clinical outcomes. Arcus also outlined first in human plans for an oral MRGPRX2 antagonist and a TNF inhibitor ahead of an upcoming ASCO symposium. For investors watching Arcus Biosciences, the fresh casdatifan data adds a new layer to the...

If you are wondering whether Range Resources at around US$41.83 is offering fair value or a margin of safety, you are not alone. This article is set up to help you frame that question with numbers, not noise. The stock has posted returns of 7.0% over the last 7 days, 15.7% over 30 days, 18.5% year to date and 19.4% over 1 year, which naturally raises questions about how much of this performance is already reflected in the current price. Recent news coverage has focused on the broader energy...

Regions Financial (NYSE:RF) announced the retirement of Dana Nolan, head of Investor Relations, after 37 years with the company. Tom Speir will assume leadership of Investor Relations, bringing experience from prior roles in strategy and treasury leadership. Regions Bank received the 2026 Gallup Exceptional Workplace Award, marking its 12th consecutive year earning this recognition. Regions Financial, the parent of Regions Bank, is a regional banking provider focused on consumer,...

If you are wondering whether Hilltop Holdings is attractively priced or starting to look expensive, you are in the right place for a closer look at what the current share price might imply. The stock most recently closed at US$37.02, with returns of 19.9% over 1 year, 9.2% year to date, 29.8% over 3 years and 6.0% over 5 years, alongside a 4.6% decline over the last 7 days and a 4.1% decline over the last 30 days. Recent share price moves sit against a backdrop of ongoing updates about...

Everspin Technologies (MRAM) closed FY 2025 with Q4 revenue of US$14.8 million and basic EPS of US$0.05, alongside net income of US$1.2 million. On a trailing 12 month basis, revenue was US$55.2 million and the business remained loss making with a basic EPS loss of US$0.03 and a net income loss of US$0.6 million. The company has seen quarterly revenue move from US$13.2 million in Q2 FY 2025 to US$14.1 million in Q3 and US$14.8 million in Q4, with EPS shifting from a loss of US$0.05 in Q1 FY...

AECOM (NYSE:ACM) has been selected by Sound Transit as the prime firm on several multi year contracts for major transit expansions in the Seattle region. The company will provide design, engineering, planning, and construction management services for new and upgraded light rail, commuter rail, and bus projects. These contracts position AECOM to play a central role in long term public transportation investments across the Pacific Northwest. For you as an investor, this new work reinforces...

What the latest results mean for New Oriental Education & Technology Group (EDU) New Oriental Education & Technology Group (EDU) recently reported accelerating revenue growth across its key segments, raised full year revenue guidance, highlighted AI and digital investments, and confirmed dividends plus an active share repurchase program. See our latest analysis for New Oriental Education & Technology Group. At a share price of US$53.31, New Oriental Education & Technology Group has seen a...

In late February 2026, Lyft reported Q4 2025 results that missed revenue and EBITDA expectations even as gross bookings and active riders reached record highs, while facing growing scrutiny from regulators, safety lawsuits, and driver safety incidents. At the same time, a U.S. House committee’s investigation into Lyft’s AI-driven pricing practices is putting its core business model and use of rider data under a brighter spotlight. We’ll now examine how these weaker-than-expected earnings and...

In recent days, reports emerged that The Trade Desk has held early talks with OpenAI about helping sell ads across ChatGPT, while CEO Jeff Green personally bought about US$148,000,000 of company stock in open-market purchases. This combination of potential exposure to a fast-growing AI platform and a large insider buy has sharpened investor focus on how The Trade Desk might extend its role as independent infrastructure for digital advertising. With these developments in mind, we'll examine...

Greg Abel, newly installed as CEO of Berkshire Hathaway, has issued his first shareholder letter outlining his priorities following Warren Buffett's retirement. Abel has committed to using his entire annual salary to buy NYSE:BRK.A shares, aiming to align his incentives closely with other shareholders. Berkshire has restarted its own share buybacks, resuming repurchases for the first time since 2024 as part of an updated capital allocation approach. Abel has reiterated Berkshire's long...

If you are wondering whether Federal National Mortgage Association's share price really lines up with its underlying worth, you are not alone. That is exactly what this article will unpack. The stock closed at US$6.92 most recently, with returns of 14.0% over the past year but a 37.1% decline year to date. This can change how investors think about both upside potential and risk. Recent attention on government sponsored mortgage giants and the broader housing finance market has kept Federal...

In February 2026, Lindsay introduced two infrastructure safety products, the Road Runner Truck-Mounted Attenuator and AlphaGuard Channelizing Device, aimed at faster, more durable, and more flexible work zone and perimeter management. These launches expand Lindsay’s portfolio in higher-value safety solutions, potentially increasing the role of infrastructure products alongside irrigation in its overall business mix. We’ll now consider how these new, rapid-deployment safety systems might...

SandRidge Energy (SD) has wrapped up FY 2025 with fourth quarter revenue of US$39.4 million and basic EPS of US$0.59, alongside trailing twelve month revenue of US$156.4 million and EPS of US$1.91 that sit against an 11.5% earnings growth figure over the past year. Over recent periods, the company has seen quarterly revenue range from US$30.1 million in Q3 2024 to US$42.6 million in Q1 2025, while basic EPS moved between US$0.35 and US$0.69 across those same quarters, setting up this latest...

Recent share performance and what it might mean for investors Pegasystems (PEGA) has attracted attention after recent trading, with the share price at $47.30 and mixed return patterns over different timeframes that may prompt investors to reassess expectations and risk tolerance. See our latest analysis for Pegasystems. Recent trading has been strong in the short term, with a 1 month share price return of 18.61% and a 7 day share price return of 4.39%. This follows a 90 day share price...

Tilray Brands has completed its acquisition of BrewDog’s global assets, including UK brewing operations and brewpubs. The company has also secured a multi year exclusive licensing agreement to produce and distribute Carlsberg beer brands in the U.S. starting in 2027. These moves expand Tilray’s presence in global beer markets and broaden its business beyond cannabis. Tilray Brands, listed as NasdaqGS:TLRY, is pushing deeper into beverages at a time when its core cannabis business remains...

In late February and early March 2026, ACADIA Pharmaceuticals reported higher full-year 2025 earnings, issued 2026 revenue guidance of US$1.22–1.28 billion, received a negative CHMP opinion on trofinetide for Rett syndrome in the EU, and added experienced finance executive Jonathan M. Poole to its Board and Audit Committee. The CHMP’s refusal of trofinetide, despite a pivotal trial meeting its key endpoints, raises important questions about ACADIA’s ability to expand Rett syndrome treatment...